Amyotrophic Lateral Sclerosis
Axoltis Pharma’s clinical research is centred on Amyotrophic Lateral Sclerosis, with an emphasis on neurological disease progression and markers linked to motor neuron degeneration. The sponsor’s trial activity in ALS reflects a focused interest in the clinical and biological features of this neurodegenerative disorder.
- Motor neuron disease
- Neurodegeneration
- Neuromuscular impairment
The research landscape includes work related to disease monitoring in ALS, with attention to neurological biomarkers and the underlying pathology of progressive functional decline.
Neurobiomarkers
The sponsor’s trial activity involves interest in blood-based indicators of neuronal injury, particularly neurofilament light chain as a marker associated with axonal damage and disease activity in ALS.
- Blood neurofilament light chain
- Biomarker surveillance
- Neuronal injury markers
This area reflects a therapeutic focus on measurable indicators that can inform the clinical understanding of neurodegenerative disease.
Blood-Brain Barrier Integrity
Axoltis Pharma also shows interest in blood-brain barrier function, with research attention directed toward biomarkers of BBB integrity in the setting of ALS. This places vascular and barrier-related neurological mechanisms within its clinical research scope.
- Blood-brain barrier
- BBB integrity
- Cerebrospinal fluid biomarkers
The sponsor’s work includes evaluation of biomarkers found in both blood and cerebrospinal fluid, supporting interest in central nervous system barrier disruption.
